Actively Recruiting
Evaluating Safety, Effectiveness, and Usability of Weekly Subcutaneous Testosterone Cypionate Auto-Injector in Adult Males with Hypogonadism
Led by Amneal Pharmaceuticals, LLC · Updated on 2026-10-27
190
Participants Needed
10
Research Sites
39 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, effectiveness, and ease of use of a weekly testosterone cypionate auto-injector in adult males with hypogonadism, a condition marked by low testosterone levels causing symptoms like low energy, reduced libido, and muscle loss. This Phase 3 study aims to determine if the auto-injector can maintain testosterone within normal ranges and to monitor side effects and participant experience with self-administration. Participants will receive weekly subcutaneous injections of testosterone cypionate into the abdomen using a prefilled auto-injector. Treatment starts at 75 mg per week, with possible adjustments to 50 mg or 100 mg depending on testosterone levels. The primary evaluation period lasts 24 weeks, followed by an optional extension phase for ongoing safety monitoring through 52 weeks. During the study, participants will attend regular clinic visits for physical exams, blood tests, hormone level measurements, and safety checks. They will complete questionnaires about symptoms, quality of life, and how easy the auto-injector is to use. Participants will also keep diaries to track self-administration and treatment adherence. The main outcome is the percentage of participants with average testosterone levels within the normal range at 12 weeks, alongside long-term safety assessments.
CONDITIONS
Brief Title
Safety and Efficacy of Weekly Testosterone Cypionate Auto-Injector in Men With Hypogonadism
Research Team
J
Janie M Gwinn, Ph.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here